secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001214659-23-004102
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro completes Phase IIA MAD trial for AL001; topline data due June 2023
--------------------------------------------------------------------------------

- Completed clinical portion of Phase IIA multiple ascending dose trial for AL001 in Alzheimer's dementia.
- AL001 is a novel lithium-delivery ionic cocrystal aiming to improve safety over current lithium treatments.
- Topline data from the MAD study expected in June 2023.
- Trial evaluated safety, tolerability, and maximum tolerated dose in mild-to-moderate Alzheimer's patients and healthy subjects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923004102/0001214659-23-004102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923004102/r3212308k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-23-004102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer